An orally disintegrating tablet including: fine granules, each fine granule having, at its center, an active pharmaceutical ingredient-containing core that includes butylscopolamine bromide and water-insoluble particles, and having an intermediate layer that includes water-insoluble particles and coats the active pharmaceutical ingredient-containing core, and a bitterness-masking layer that includes talc and at least one water-insoluble polymer, in sequence from the active pharmaceutical ingredient-containing core side; and an excipient component positioned on the outside of the fine granules, and a method for producing the same.

“PHARMACEUTICAL COMBINATION CONTAINING AN ANALGESIC AGENT AND AN ANTISPASMODIC AGENT”, whose analgesic agent is the Ketorolac Tromethamine, which is physically isolated from the antispasmodic agent and whose antispasmodic active ingredient, in combination with the analgesic agent Ketorolac Tromethamine, is Hyoscine, Pargeverine, Tolterodine, Mebeverine or Papaverine. Both the analgesic agent Ketorolac Tromethamine and the antispasmodic agent are combined in separate and immediate release form. The analgesic agent Ketorolac Tromethamine can also be found in the present combination in separate and immediate release form, while the combined antispasmodic agent is presented in equally separate, but programmed release form. The active ingredient Ketorolac Tromethamine is in a ratio between 2.5% and 20% by weight and the antispasmodic active ingredient is in a ratio between 2.5% and 20% by weight.

This invention provides compounds of formula I:

##STR00001##

wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

Disclosed are compositions containing an extract of Serenoa repens, a lipophilic extract of Zingiber officinalis and a lipophilic extract of Echinacea angustifolia or Zanthoxylum bungeanum.

This invention provides compounds of formula I: ##STR00001##
wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

Embodiments of the present invention are directed to a plurality of substantially spherical microspheres comprising at least one API substantially dispersed in at least one polymer and a lyoprotectant on an outside surface of the plurality of substantially spherical microspheres, wherein the plurality of substantially spherical microspheres have a D99[num] particle diameter of less than about 10 μm; a D90[num] circularity value of from about 0.8 to about 1.0; and comprise API in a weight of about 20 to about 40 wt. % of the polymer. Other embodiments relate to injectable compositions comprising such microspheres and methods of treating a number of conditions by administering such injectable compositions to a subject.

The present invention relates to a novel proteolytically active polypeptide and various uses of the polypeptide (and others) in screening and manufacturing methods.

A proteolytically active polypeptide comprising an acid sequence having at least 50% sequence identity with the sequence of SEQ ID NO: 1 with the proviso that the polypeptide does not comprise the amino acid sequence of SEQ ID NO: 1. A nucleic acid encoding the polypeptide. An antibody specifically binding to the polypeptide. A method for the manufacture of a proteolytically processed polypeptide comprising contacting a first polypeptide having at least 50% sequence identity to SEQ ID NO: 1 with a second polypeptide that is susceptible to proteolysis by said first polypeptide.

The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.

The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.